Abstract
Recent animal studies demonstrated that some kind of growth factors can ameliorate neurological deficits and bone marrow stromal cells (MSCs) transplantation also can improve neurological function after ischemic stroke. MSCs, including the primitive pluriopotent mesenchmal stem cell, are attractive targets for cell and gene therapy. When long-term stable expression of a potentially therapeutic transgene is desired, as is the case for the treatment of cerebrovascular diseases, it may be appropriate to employ some viral vectors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
